Alto Neuroscience (ANRO) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 27, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 2 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about ANRO filings

Are insiders buying or selling Alto Neuroscience, Inc. (ANRO) stock?

Neither. Alto Neuroscience, Inc. (ANRO) insiders filed no open-market purchases or sales in the 90 days to Oct 27, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ANRO recently?

None. No member of Congress disclosed a ANRO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ANRO smart-money data?

This summary uses filings available on Oct 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on ANRO

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ANRO filings

Are insiders buying or selling Alto Neuroscience, Inc. (ANRO) stock?

Neither. Alto Neuroscience, Inc. (ANRO) insiders filed no open-market purchases or sales in the 90 days to Oct 27, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ANRO recently?

None. No member of Congress disclosed a ANRO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ANRO smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$54.6MSells/Trims$17.3M

Buys/Adds (2)

BR
BlackRock
Q2 2026 13F
$41.0M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
SS
State Street
Q2 2026 13F
$13.6M
added

Sells/Trims (1)

P7
Point72
Steven Cohen · Q1 2026 13F
$17.3M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 12, 2026

Earnings came in 8.5% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 12, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.65+8.45% beat

-$0.71 expected

Revenue

Unavailable

Revenue data unavailable

Next report

Estimated report: Nov 11, 2026, in 15 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 12, 2026	-$0.65 / -$0.71Alpha Vantage	+8.45% beat	Unavailable	Unavailable
Mar 31, 2026	May 13, 2026	-$0.80 / -$0.50Alpha Vantage	-60.00% miss	Unavailable	Unavailable
Dec 31, 2025	Mar 16, 2026	-$0.45 / -$0.66Alpha Vantage	+31.82% beat	Unavailable	Unavailable
Sep 30, 2025	Nov 12, 2025	-$0.52 / -$0.64Alpha Vantage	+18.75% beat	Unavailable	Unavailable
Jun 30, 2025	Aug 13, 2025	-$0.65 / -$0.60Alpha Vantage	-8.33% miss	Unavailable	Unavailable
Mar 31, 2025	May 14, 2025	-$0.56 / -$0.62Alpha Vantage	+9.68% beat	Unavailable	Unavailable
Dec 31, 2024	Mar 20, 2025	-$0.52 / -$0.55Alpha Vantage	+5.45% beat	Unavailable	Unavailable
Sep 30, 2024	Nov 12, 2024	-$0.62 / -$0.64Alpha Vantage	+3.13% beat	Unavailable	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Open: $21.95
52-wk high: $37.48
High: $22.45
52-wk low: $10.20
Low: $21.45
Prev close: $22.20
Mkt cap: $862.1M
ROE: -49.2%
Beta: 1.34
P/B: 5.4x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $862M

Valuation

P/B5.37

Quality

Operating margin0.0%
ROE-49.2%
ROA-26.8%

Growth

Beta1.34

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

40balanced

20D volatility

56%annualized

52-week range

$21.97

$10.20$37.48

20D support

$21.32recent floor

20D resistance

$27.76recent ceiling

Returns

5D +0.1%20D -17.1%60D -23.3%

Price vs moving averages

SMA20 -7.6%SMA50 -25.2%SMA200 -8.8%

Volume pace

1.21xvs prior 20D

Period ending

Reported

EPS / estimate

EPS surprise

Revenue / income

Surprise

Jun 30, 2026

Aug 12, 2026

-$0.65 / -$0.71Alpha Vantage

+8.45% beat

Unavailable

Mar 31, 2026

May 13, 2026

-$0.80 / -$0.50Alpha Vantage

-60.00% miss

Unavailable

Dec 31, 2025

Mar 16, 2026

-$0.45 / -$0.66Alpha Vantage

+31.82% beat

Unavailable

Sep 30, 2025

Nov 12, 2025

-$0.52 / -$0.64Alpha Vantage

+18.75% beat

Unavailable

Jun 30, 2025

Aug 13, 2025

-$0.65 / -$0.60Alpha Vantage

-8.33% miss

Unavailable

Mar 31, 2025

May 14, 2025

-$0.56 / -$0.62Alpha Vantage

+9.68% beat

Unavailable

Dec 31, 2024

Mar 20, 2025

-$0.52 / -$0.55Alpha Vantage

+5.45% beat

Unavailable

Sep 30, 2024

Nov 12, 2024

-$0.62 / -$0.64Alpha Vantage

+3.13% beat

Unavailable

Alto Neuroscience, Inc.

Smart money at a glance

What do analysts expect?

Questions about ANRO filings

Smart money on ANRO

Questions about ANRO filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 8.5% above what analysts expected.

Estimated report: Nov 11, 2026, in 15 days

Previous reports

Is the business strong?

Price structure

Alto Neuroscience, Inc.

Smart money at a glance

What do analysts expect?

Questions about ANRO filings

Smart money on ANRO

Questions about ANRO filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 8.5% above what analysts expected.

Estimated report: Nov 11, 2026, in 15 days

Previous reports

Is the business strong?

Price structure

Alto Neuroscience, Inc.

Overview

Questions about ANRO filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Alto Neuroscience, Inc.

Overview

Questions about ANRO filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals